Astrazeneca

Teva closer to SICOR merger

Teva closer to SICOR merger

Israel's Teva has moved a step closer to consolidating its position
as the world's biggest generics manufacturer with the $3.4 billion
(€2.7bn) acquisition of US-based SICOR, which makes active
pharmaceutical ingredients...

Finding the right fold

Finding the right fold

Pharmaceutical giant AstraZeneca has enlisted the aid of small
Hungarian firm RecomGenex to produce fully-functional versions of
nuclear receptors used in drug discovery.

NME approvals on the rise?

NME approvals on the rise?

The US Food and Drug Administration (FDA) approved 15 New Molecular
Entities in the current year to 30 September, 2003, setting the
stage to outpace last year's registrations by nearly 20 per cent,
says a report from Cutting...

Investing in drug discovery

Investing in drug discovery

Iceland-based deCODE genetics announced this week that AstraZeneca
has entered into an agreement to purchase its RoboHTC automated
protein crystallography platform, earmarked for AstraZeneca's drug
discovery sites in Alderley...

Spotlight

Follow us

Products

View more

Webinars

Featured Suppliers

All suppliers